Engflag

Maxalt Rapitab

Quick links to important sections

Maxalt Rapitab

Maxalt Rapitab_EN

Method of action: Analgesic

Treatment option: Headache, Migraine

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxalt Rapitab

Property Description
Active ingredient Rizatriptan benzoate
Form Orally Disintegrating Tablet (ODT) / Lyophilisate
Pharmacological class Selective Serotonin 5-HT1B/1D Receptor Agonist (Triptan)
Common use Acute Antimigraine Agent
Origin Synthetic Compound

Maxalt Rapitab: Identity and Pharmacological Classification

Maxalt Rapitab is a dedicated, synthetic prescription medicine whose active component is Rizatriptan benzoate. It is classified within the Triptan pharmacological group, which are formally designated as selective serotonin 5-HT1B/1D receptor agonists. This compound is engineered to interact specifically with certain neuroreceptors to manage the acute physical processes associated with severe head pain episodes. Its effectiveness in this role is clinically recognized within pharmacological medicine.

Composition and The Orally Disintegrating Form (ODT)

This product is a single active ingredient product, containing only Rizatriptan benzoate. A key differentiating feature of the specific preparation is its dosage form: an orally disintegrating tablet (ODT), also described as a wafer or lyophilisate, designed for simple oral administration. The ODT form provides a convenient delivery system that dissolves rapidly on the tongue without the need for water, which is particularly beneficial for patients who experience symptoms like nausea or vomiting during a severe head pain episode. Clinical pharmacology confirms that the rapid dissolution of the ODT formulation is a key factor in its function as an acute interventional agent.

General Purpose as an Acute Antimigraine Agent

The general purpose of this medication is to serve as an antimigraine agent used for the acute therapy of established severe head pain. Its role is to interrupt the progression of the pain episode once it has begun. The drug's Triptan class action is based on the principles of neurotransmitter modulation and selective cranial vasoconstriction, which are the fundamental mechanisms by which it is intended to bring relief by addressing the underlying neurovascular cause. The product's formulation is specifically positioned for situations requiring prompt and non-liquid administration.

Regulatory References

  1. Triptans - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Maxalt Rapitab?

Possible Side Effects and Safety Information

The safety profile for Maxalt Rapitab (rizatriptan benzoate) is established through regulatory review and is categorized based on the frequency and system-organ class of reported reactions in official documents.

Adverse Reactions by Frequency

Adverse reactions are formally classified according to how often they have been observed, adhering to regulatory standards:

Classification Examples of Officially Documented Effects
Common (geq1/100 to <1/10) Dizziness, somnolence, fatigue, nausea, dry mouth, and sensations of pressure, heaviness, or pain in the chest, throat, or neck.
Uncommon (geq1/1,000 to <1/100) Palpitation, tachycardia, hypertension, vertigo, rash, pruritus.
Rare (geq1/10,000 to <1/1,000) Hypersensitivity reaction, anaphylaxis, angioedema.

Serious Adverse Reactions and Safety Constraints

Official labeling documents severe, though rare, safety concerns, reflecting the known Triptan class effects. These include myocardial ischaemia or infarction, cerebrovascular events (e.g., stroke), and Serotonin Syndrome, particularly when used with certain other medications.

Maxalt Rapitab is strictly contraindicated (should not be used) in patients with a history of ischemic heart disease, uncontrolled hypertension, or stroke. It is also contraindicated for use with MAO-A inhibitors or within 24 hours of other Triptans or ergotamine-type drugs due to the risk of additive vasospastic effects. Furthermore, the medicine is contraindicated in patients with severe hepatic or severe renal insufficiency.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Rizatriptan benzoate based on documented clinical manifestations and required emergency procedures. Immediate medical attention is required for any suspected overdose due to the potential for severe cardiovascular and central nervous system effects.

Potential Manifestations (High Doses) Required Emergency Action
Dizziness, Somnolence, Vomiting Seek Immediate Medical Attention
Syncope (Fainting), Incontinence Initiate Symptomatic and Supportive Treatment

Overdosage carries a serious risk of life-threatening cardiovascular outcomes, including Bradycardia, which may progress to a serious rhythm disturbance like a third degree AV block. Furthermore, based on regulatory documentation, elevated Hypertension and Myocardial Ischemia are possible events that must be considered.

Since no specific antidote is known, the mandated management protocol focuses on supportive care. This regulatory guidance includes the consideration of gastrointestinal decontamination (such as gastric lavage and activated charcoal) and requires continuous clinical and electrocardiographic (ECG) monitoring for a mandatory period of at least 12 hours. This period of observation is required even if initial clinical symptoms are not readily apparent. In pediatric patients, high-dose exposure has also been associated with adverse reactions such as abdominal discomfort, fatigue, and dyspnea.

Therapeutic Uses of Maxalt Rapitab

What Maxalt Rapitab Treats: Main Uses and Benefits

Maxalt Rapitab is specifically used for the acute management of established migraine attacks in adult patients and adolescents (6–17 years old). This medicine is relevant for patients suffering from migraine with aura and migraine without aura. It is utilized in clinical settings marked by heightened patient distress, particularly when symptoms are moderate or severe in intensity, and provides symptomatic relief to ease the overall symptom burden. The primary therapeutic benefit is to manage the acute episode, aiming to assist with easing the intense, throbbing head pain and assists with maintaining functional stability.

It helps manage the symptom clusters that often accompany a typical migraine, including the pronounced sensitivities to light (photophobia) and sound (phonophobia). This supportive relief helps patients cope more steadily with difficult episodes.

The orally disintegrating tablet form offers a practical advantage in scenarios where migraine-related nausea or vomiting complicates swallowing traditional pills.

Quick Fact: Relief for Migraine-Related Sensory Distress

The medication supports the patient in taking the medication in situations involving acute or disruptive symptom patterns, which may contribute to easing the overall symptom load and supports improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. Official Rizatriptan Prescribing Information (DailyMed)

Eligibility and Restrictions for Use

Eligibility for Maxalt Rapitab (rizatriptan benzoate) is defined by official regulatory labeling, primarily based on patient age and pre-existing medical conditions. The medicine is approved for use in adults and adolescents (ages 6 to 17) for the acute treatment of migraine attacks.

Absolute Contraindications

Maxalt Rapitab must not be used in patients with:

  • Ischemic Heart Disease: Including angina pectoris, history of myocardial infarction, or documented silent ischemia.
  • Cerebrovascular Disease: Including history of stroke or transient ischemic attack (TIA).
  • Vascular Conditions: Coronary artery vasospasm (Prinzmetal's angina), peripheral vascular disease, or uncontrolled hypertension.
  • Specific Migraines: Hemiplegic or basilar migraine.
  • Severe Organ Impairment: Severe hepatic insufficiency.
  • Concurrent Medication: Use within 24 hours of other triptans or ergotamine-type drugs, or within two weeks of stopping an MAO-A inhibitor.

Conditional and Restricted Use

Population Group Eligibility Status (Regulatory Label)
Children (Under 6 years) Safety and effectiveness have not been established.
Elderly Patients (Over 65 years) Caution advised; not systematically evaluated.
Pregnancy/Lactation Conditional use; permitted only if benefit justifies potential risk.
Mild-to-Moderate Hepatic Impairment Use requires dose restriction (5 mg dose).

These constraints ensure the drug is used strictly within populations where its safety profile has been officially deemed acceptable.

What should I know about interactions with other medicines?

Maxalt Rapitab (rizatriptan) is known to interact with certain medications, which can potentially increase the risk of side effects, including a serious condition called serotonin syndrome.

Contraindicated Combinations

Certain drugs should never be taken concurrently with Maxalt Rapitab. These combinations are generally avoided due to significant risk:

  • Monoamine Oxidase Inhibitors (MAOIs): Including phenelzine and tranylcypromine. Maxalt Rapitab must not be used concurrently or within 14 days of stopping an MAOI.
  • Other Triptans: Such as sumatriptan, zolmitriptan, or eletriptan. These should be avoided within 24 hours of taking Maxalt Rapitab.
  • Ergot-Containing Medications: Including ergotamine and dihydroergotamine. These should also be avoided within 24 hours of taking Maxalt Rapitab.
Drug Class/Example Interaction Risk
SSRIs/SNRIs (e.g., fluoxetine, venlafaxine) Increased risk of serotonin syndrome
Propranolol Increases rizatriptan blood levels; lower Maxalt dose may be required

It is essential to inform your healthcare provider about all prescription drugs, over-the-counter medicines, and herbal supplements (such as St. John's Wort) you are currently taking to properly manage potential interactions and adjust dosing as necessary.

Mechanism of Action

Maxalt Rapitab (rizatriptan) initiates a coordinated physiological response by acting as a highly selective agonist on specific serotonin 5 -HT1 B and 5 -HT1 D receptors within the trigeminovascular system.

Its mechanism involves a targeted, triple-action cascade which modulates the neurovascular process. The 5 -HT1 B receptors are located on the smooth muscle of extracerebral cranial arteries; their activation initiates a shift in vascular tone, triggering selective vasoconstriction to regulate excessive vessel dilation.

Simultaneously, the 5 -HT1 D receptors are engaged on peripheral nerve endings and in the brainstem. Activation of these receptors suppresses the release of vasoactive neuropeptides such as CGRP, thereby modulating the neurogenic inflammation pathway. This action limits the upstream propagation of these mediators while blocking the upward transmission of nociceptive signals in the central nervous system, resulting in modulation of sensory nerve activity.

Dosage and Administration Information

How to Use Maxalt Rapitab: Official Administration Guidelines

Maxalt Rapitab (rizatriptan benzoate) is authorized for oral administration as an acute, intermittent treatment for established migraine attacks; it is not for prophylactic use. Usage is governed by maximum dose limits and mandatory time intervals to align with established therapeutic standards.

Dosing and Frequency

The standard adult regimen begins with a single dose of 5 mg or 10 mg. If the headache recurs, a second dose may be administered, but a minimum of two hours must elapse after the first dose. The cumulative intake for adults must not exceed 30 mg within any 24-hour period.

Administration of the ODT Form

As an Orally Disintegrating Tablet (ODT), the medicine is designed to dissolve quickly on the tongue and is swallowed with saliva; no water or liquid is required. To maintain the integrity of the tablet, the ODT should be removed from its blister using dry hands immediately prior to administration.

Specific Population Instructions

For pediatric patients (aged 6 to 17), the dose is weight-dependent: 5 mg for those weighing less than 40 kg, and 10 mg for those 40 kg or more. A reduced dose of 5 mg is considered for patients with mild to moderate hepatic or renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Trial Design and Primary Outcomes

Trials have been conducted to investigate the agent rizatriptan for the acute management of migraine attacks, with or without aura. The orally disintegrating tablet (Maxalt Rapitab or Maxalt-MLT) formulation has been specifically evaluated in clinical settings.

  • RCTs in Adults: Studies assessed the agent's effects compared to placebo in reducing pain severity from moderate or severe to mild or no pain at two hours post-dose. These trials involved over a thousand adult participants.
  • Efficacy Endpoints: Key findings from a meta-analysis showed that the agent was associated with improvements in patient-reported quality of life compared to placebo. Study data included an evaluation of various dose levels, with the 10 mg dose generally showing a greater effect compared to the 5 mg dose in pain relief at two hours.

Adverse Event Reporting and Subgroup Analysis

Research has explored the agent's effects in specific patient groups, including children and adolescents, and long-term use for up to a year.

  • Pediatric Studies: Clinical research evaluated the agent's effects in pediatric patients aged 6 to 17 years using a weight-based dosing strategy, comparing outcomes to placebo.
  • Adverse Event Reporting: The adverse event profile was documented in controlled studies. The most frequently observed adverse events included dizziness, somnolence (drowsiness), and asthenia (fatigue). Trial records noted the circumstances under which study participation was discontinued.
  • Safety Monitoring: The duration of observation was documented in long-term studies lasting up to 12 months. Research also investigated the agent in relation to cardiovascular outcomes, as this class of medicine may cause coronary artery vasospasm.

Key Studies & References Headache: diagnosis and management (NICE Guideline NG196)

How should Maxalt Rapitab be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling dictates the specific storage and handling conditions for Maxalt Rapitab (rizatriptan benzoate orally disintegrating tablets) to ensure product stability and safety.

Storage Conditions

  • Temperature: Maxalt Rapitab must be stored at controlled room temperature, typically maintained between 15°C and 30°C (59°F and 86°F). The product must be kept from freezing and excessive heat.
  • Protection: The medicine must be kept in its original packaging, tightly closed, and protected from light and moisture.
  • Packaging Rule: Do not remove the sensitive wafer blister from its outer pouch until just prior to use.
  • Child Safety: The medication must be kept out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Maxalt Rapitab must adhere to official protocols. Patients should consult a pharmacist or healthcare professional for guidance. The official method is often through a drug take-back program or by returning the medicine to a local pharmacy, as general environmental release must be avoided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagFinland

Equivalent of Maxalt Rapitab found in:

A-Z Index: